From the June 2015 issue of HealthCare Business News magazine
At the end of April, I had dinner with three people at Nino’s Restaurant in New York City.
Nino’s is popular with celebrities and the owner, Nino Selimaj, is friends with many of them. Personally, I felt like I was among celebrities from our industry, as I shared a table with three people deeply grounded in molecular imaging.
In attendance were Dr. Stanley Goldsmith (who recommended Nino’s restaurant), James Reiss, and Don Bogutski. Goldsmith is the past president of the Society of Nuclear Medicine and has been actively involved with the society for more than four decades, and he is also Director-Emeritus and Professor of Radiology and Medicine at Weill Cornell Medical College. Reiss is the president of Biodex Medical Systems, which manufactures molecular imaging accessories.
In three days Biodex turns raw steel into finished products and ships them to 85 countries around the world. Last, but certainly not least, Bogutski has been the president of Diagnostix Plus, a supplier of molecular imaging capital equipment, for 32 years. As you can imagine, we talked about a number of very interesting topics related to molecular imaging.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Goldsmith talked about an article that he once wrote on the role of radioiodine in diagnostic imaging and targeted radionuclide therapy. I will not go into details here because I am hoping that we can convince him to share it with us, but it is a very interesting analysis of the role that iodine has played in health care over the years.
A shift in tradition
The main topic of conversation focused on the future of the molecular imaging sector. For instance, there is a trend nowadays on the part of radiologists to interpret molecular imaging studies. Some cynics would say this is to generate additional income opportunities.
Physicians who are seeking designation as Authorized Users, which would enable them to use radio-nuclides for therapy, can do so now based on the observation of just 6 cases. Goldsmith believes more experience (perhaps 50 cases) is appropriate to better appreciate eligibility criteria, dose selection and patient management. He believes it is vital for physicians to get that level of training in molecular imaging because the discussion and intricacies of each individual case serves to give a professional a better understanding of what to look for and what to disregard when it comes to interpreting images.